Abstract
There is an urgent need for new antimycobacterial drugs, and in particular for novel agents that will shorten the duration of tuberculosis chemotherapy, or overcome drug-resistant strains of the causative organism, Mycobacterium tuberculosis. Our knowledge of the tubercle bacillus and its complex interaction with the human host has improved dramatically in recent years, particularly with the determination of its complete genome sequence. New genome-scale tools are being applied to aid in drug target identification, alongside traditional approaches aimed at understanding the basic biology of M. tuberculosis. Many potential drug targets have been identified, but very few have been validated by showing that they are essential for growth or survival of the bacterium. In this review, the landscape of potential drug targets is surveyed.
Keywords: tuberculosis, mycobacterium tuberculosis, genomic sequencing, microarray technology, mycolic acid, regulatory proteins, smegmatis
Current Pharmaceutical Design
Title: Identification and Validation of Novel Drug Targets in Tuberculosis
Volume: 10 Issue: 26
Author(s): K. Duncan
Affiliation:
Keywords: tuberculosis, mycobacterium tuberculosis, genomic sequencing, microarray technology, mycolic acid, regulatory proteins, smegmatis
Abstract: There is an urgent need for new antimycobacterial drugs, and in particular for novel agents that will shorten the duration of tuberculosis chemotherapy, or overcome drug-resistant strains of the causative organism, Mycobacterium tuberculosis. Our knowledge of the tubercle bacillus and its complex interaction with the human host has improved dramatically in recent years, particularly with the determination of its complete genome sequence. New genome-scale tools are being applied to aid in drug target identification, alongside traditional approaches aimed at understanding the basic biology of M. tuberculosis. Many potential drug targets have been identified, but very few have been validated by showing that they are essential for growth or survival of the bacterium. In this review, the landscape of potential drug targets is surveyed.
Export Options
About this article
Cite this article as:
Duncan K., Identification and Validation of Novel Drug Targets in Tuberculosis, Current Pharmaceutical Design 2004; 10 (26) . https://dx.doi.org/10.2174/1381612043383223
DOI https://dx.doi.org/10.2174/1381612043383223 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis, Screening and Docking Analysis of Novel Benzimidazolium and Benzotriazolium Compounds as Potent Anti Tubercular Agents
Anti-Infective Agents Benzothiazole-based Compounds in Antibacterial Drug Discovery
Current Medicinal Chemistry Identification of Active Phytochemical from Traditional Herbal Knowledge-base Targeting Pantothenate Synthetase for Anti-tuberculosis Therapy
Letters in Drug Design & Discovery Prevalence of Oral and Systemic Manifestations in Pediatric HIV Cohorts with and without Drug Therapy
Current HIV Research Association Between Polymorphism of SDF1 (CXCL12) Gene and HIV-1 Susceptibility: A Meta-Analysis
Current HIV Research Essential Oils with Microbicidal and Antibiofilm Activity
Current Pharmaceutical Biotechnology Catheter Related Line Sepsis Resulting from Mycobacterium <i>chelonae</i> Infection in an Immunocompromised Host
Infectious Disorders - Drug Targets Applying Knowledge of Enzyme Biochemistry to the Prediction of Functional Sites for Aiding Drug Discovery
Current Topics in Medicinal Chemistry <i>Dichrostachys cinerea</i>: Ethnomedicinal Uses, Phytochemistry and Pharmacological Activities - A Review
The Natural Products Journal Biological and Chemical Diversity of Coral-Derived Microorganisms
Current Medicinal Chemistry SV40 and HIV Sequences in the Cerebrospinal Fluid of a Patient with AIDS Dementia Complex
Current HIV Research Copper (II) – HisAibGly Complex and Its Superoxide Dismutase Activity (Suplementary Material)
Protein & Peptide Letters Seco-Tetracyclic and Seco-Pentacyclic Triterpenoids from Nature: Phytochemistry, Biological Activity: A Review
Mini-Reviews in Organic Chemistry Recent Advances in New Structural Classes of Anti-Tuberculosis Agents
Current Medicinal Chemistry Non-Antidepressant Treatment of Social Anxiety Disorder: A Review
Current Clinical Pharmacology Statistical Molecular Design of Balanced Compound Libraries for QSAR Modeling
Current Medicinal Chemistry Quinoxaline 1,4-di-N-Oxide Derivatives: Are They Unselective or Selective Inhibitors?
Mini-Reviews in Medicinal Chemistry Nearly 200 X-Ray Crystal Structures of Transthyretin: What Do They Tell Us About This Protein and the Design of Drugs for TTR Amyloidoses?
Current Medicinal Chemistry The Current View on the Helicase Activity of RNA Helicase A and Its Role in Gene Expression
Current Protein & Peptide Science p53-Induced Apoptosis and Inhibitors of p53
Current Medicinal Chemistry